AstraZeneca to take $381.5 million charge after two major trial failures
This article was originally published in Scrip
Executive Summary
Hit by two major clinical trial disappointments in quick succession, AstraZeneca said it would take pre-tax impairment charges totalling $381.5 million to R&D expense in the fourth quarter of 2011.